D
Pharvaris N.V. PHVS
$28.10 $3.9816.50% NASDAQ
Recommendation
Prev Close
$24.12
Volume
1,923,120
Avg Vol (90D)
214,623
Market Cap
$1.57B
Dividend & Yield
--
52-Week Range
$11.51 - $28.63
P/E (TTM)
--
EPS (TTM)
-$3.22
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
Pharvaris (NASDAQ:PHVS) Sees Strong Trading Volume - Here's Why
12/3/2025 - Ticker Report
Pharvaris (PHVS) Surges 18% Following Positive Phase 3 Trial Results
12/3/2025 - GuruFocus
Pharvaris achieves primary goal in late-stage trial of deucrictibant for HAE
12/3/2025 - SeekingAlpha.com: All News
Pharvaris achieves primary goal in late-stage trial of deucrictibant for HAE
12/3/2025 - Seeking Alpha - Healthcare
Pharvaris Surges, Pulling KalVista Out Of A Slump, On Promising New HAE Treatment
12/3/2025 - Yahoo! Finance: News
Pharvaris Pill Provides Rapid Relief In Patients With Rare Swelling Attacks, Data Shows
12/3/2025 - Benzinga
Futures Rise As Bitcoin Extends Rally For 2nd Day, Copper Hits Record
12/3/2025 - Zero Hedge
PHVS Stock Jumps After Phase 3 Trial Shows Rapid Symptom Relief For Oral HAE Treatment
12/3/2025 - Stocktwits News Feed
Pharvaris (PHVS) Advances Deucrictibant for Hereditary Angioedema Treatment
12/3/2025 - GuruFocus
Pharvaris Announces Positive Topline Data from RAPIDe-3 Pivotal Study Confirming Potential of ...
12/3/2025 - GuruFocus
Pharvaris' deucrictibant meets primary endpoint in HAE attack trial
12/3/2025 - The Fly
Pharvaris Announces Positive Topline Data from RAPIDe-3 Pivotal Study Confirming Potential of Deucrictibant for On-Demand Treatment of HAE Attacks
12/3/2025 - Globe Newswire
pharvaris clocks pivotal win race rapid hae relief teeing filing challenge kalvista
12/3/2025 - FierceBiotech.com - Biotech
A $68 Million Signal: What General Atlantic Sees in Pharvaris Right Now
12/3/2025 - Nasdaq News: Markets
A $68 Million Signal: What General Atlantic Sees in Pharvaris Right Now
12/3/2025 - Fool.com Headlines
Pharvaris (NASDAQ:PHVS) Shares Down 4.8% - Time to Sell?
12/2/2025 - Ticker Report
Pharvaris (PHVS, $26) RSI Indicator left the overbought zone on December 01, 2025
12/2/2025 - Tickeron - Stocks
Pharvaris (NASDAQ:PHVS) Sets New 1-Year High - What's Next?
11/28/2025 - MarketBeat
Pharvaris (NASDAQ:PHVS) Sees Large Volume Increase - Still a Buy?
11/27/2025 - MarketBeat
Pharvaris (PHVS, $27.72) RSI Indicator left the overbought zone on November 26, 2025
11/27/2025 - Tickeron - Technical Analysis
Pharvaris (PHVS, $27.72) price may drop as it broke higher Bollinger Band on Nov 26, 2025
11/27/2025 - Tickeron - Technical Analysis
Pharvaris (NASDAQ:PHVS) Sets New 1-Year High - What's Next?
11/27/2025 - Ticker Report
Pharvaris Reports Q3 2025 Financial Results and Updates
11/27/2025 - TipRanks Financial Blog
Did Analyst Optimism on PHVS Pipeline Outweigh Continued Losses in Pharvaris' Latest Results?
11/25/2025 - Simply Wall St
Pharvaris: Biotech With De-Risked Phase 3 Readout Coming, Initiating With A Buy Rating
11/23/2025 - Seeking Alpha - Long Ideas
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
-$184.46M
EBIT (TTM)
-$184.65M
Net Income (TTM)
-$180.86M
Balance Sheet
Total Assets (Q)
$397.63M
Total Debt (Q)
$678.90K
Total Liabilities (Q)
$31.27M
Book Value Per Share (Q)
$5.64
Cash Flow
Cash from Operations (TTM)
-$147.63M
Cash from Investing (TTM)
-$343.90K
Cash from Financing (TTM)
$188.06M
Net Change in Cash (TTM)
$37.12M
Filings
Filing Date
Wednesday, November 12, 2025
Period Date
Tuesday, September 30, 2025
Next Filing
Week of Apr 6 and 10 (est)
Price History
Loading...
Beta
0.78
7-Day Total Return
13.17%
30-Day Total Return
17.13%
60-Day Total Return
17.38%
90-Day Total Return
40.50%
Year to Date Total Return
51.56%
1-Year Total Return
42.06%
2-Year Total Return
54.23%
3-Year Total Return
1,291.09%
5-Year Total Return
--
52-week Low
Apr 10, 2025 - $11.51
52-week High
Dec 01, 2025 - $28.63
Valuation
Market Cap
$1.57B - Small Cap
Enterprise Value
$1.18B
Price/Sales (TTM)
--
Price/Book (Q)
4.28
Dividends and Shares
Shares Outstanding
62.26
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
pharvaris.com
Phone Number
31 712036410
Address
Grafenauweg 8
Zug, 6300
Country
Switzerland
Year Founded
2015
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other... more
NASDAQ 12/03/2025 12:01PM Eastern Quotes delayed